Arthritis Innovation Corporation (AIC) is a clinical-stage pharmaceutical company addressing unmet needs in orthopedic surgery and arthritis management.
A private company founded in 2013, AIC leverages a world-class product development team located in Toronto, Canada and Denver, Colorado, and a proprietary polymer drug delivery system (BEPO®) formulated with previously marketed drugs.
AIC's first drug in clinical development brings sustained, local delivery of a well-known NSAID for the management of pain and inflammation after total knee replacement (TKR) surgery, as an alternative to narcotics or oral NSAIDs.
Completed Phase 2 Study: Clinicaltrials.gov: NCT03541655. For more information, click HERE.
Upcoming Phase 3 Safety Arm: Clinicaltrials.gov: NCT04860635. For more information, click HERE.